Anticholinergic News and Research

RSS
GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

GSK, Theravance announce availability of Anoro Ellipta in the US for COPD treatment

New edition of RADAR includes review of glycopyrronium for COPD treatment

New edition of RADAR includes review of glycopyrronium for COPD treatment

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

New needle-free treatment may dramatically reduce global snakebite fatalities

New needle-free treatment may dramatically reduce global snakebite fatalities

Exposure to excessive heat can lead to heatstroke

Exposure to excessive heat can lead to heatstroke

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Researchers find that over 40% of patients treated for COPD did not actually have the disease

Researchers find that over 40% of patients treated for COPD did not actually have the disease

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

COPD phase III study by Almirall and Forest Laboratories announces positive results

COPD phase III study by Almirall and Forest Laboratories announces positive results

FDA approves Allergan’s BOTOX to treat overactive bladder

FDA approves Allergan’s BOTOX to treat overactive bladder

Tiotropium benefits patients with chronic obstructive pulmonary disease

Tiotropium benefits patients with chronic obstructive pulmonary disease

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication as effective as Botox injections for treating incontinence in women

Botox injections effectively treat urinary urgency incontinence in women

Botox injections effectively treat urinary urgency incontinence in women

Multicomponent strategies needed to prevent in-hospital delirium

Multicomponent strategies needed to prevent in-hospital delirium

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.